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Analysis of clinical and dosimetric factors associated with severe 
radiation pneumonitis in locally advanced Non-Small-Cell-Lung-
Cancer patients treated with concurrent chemotherapy and 
intensity-modulated radiotherapy (IMRT)
Shi, Anhui; Zhu, Guangying; Yu, Rong; Li, Fuhai; Li, Dongming; Sun, 
Yan; Xu, Bo 
Department of Radiation Oncology, Cancer Hospital, School of Oncol-
ogy, Peking University, Beijing, China
Purpose: To retrospectively evaluate clinical and dosimetric factors 
associated with severe (grade≥3) radiation pneumonitis in patients 
after concurrent chemotherapy and intensity-modulated radiotherapy 
(IMRT).
Methods: We retrospectively analyzed 94 locally advanced NSCLC 
patients treated with concurrent chemotherapy and IMRT between 
May 2005 and September 2006. Radiation pneumonitis was graded 
according to Common Terminology Criteria for Adverse Events version 
3.0. The following clinical parameters were considered: gender, age, 
smoking and diabetes history, history of chronic obstructive pulmonary 
disease (COPD), induction chemotherapy, concurrent chemotherapy 
regimens, performance status and forced expiratory volume in 1 second 
(FEV1). Dosimetric factors including mean lung dose (Dmean), rV5-
V60 relative volumes of lung receiving more than a threshold dose D 
of radiation (rVD), where values of D considered were 5˚C 60 Gy in 
increments of 5 Gy), prescribed dose (63GY/35f/7w vs 60Gy/30f/6w), 
and normal tissue complication probability (NTCP) values were 
analysed. DVHs data and NTCP values were collected for both lungs 
considered as a parallel organ. Pearson Chi-Square test was performed 
to compare clinical parameters between patients who developed severe 
RP and those who did not. Univariate and multivariate logistic regres-
sion analyses were performed to evaluate data for association between 
clinical and dosimetric factors and severe RP. The study was approved 
by the institutional reviewboard. 
Results: Of 94 patients, 11 (11.7%) develop severe (grade≥3) radiation 
pneumonitis; 6 (6.4%), grade 3; 2(2.1%), grade 4; and 3 (3.2%)grade 
5. Univariate analyses show that Sex, age (≤60vs>60), smoking and 
diabetes history, induction chemotherapy, concurrent chemotherapy 
regimens, PS(≤70vs>70) and prescribed dose did not signiﬁcantly dif-
fer between patients who developed severe RP and those who did not. 
However, NTCP, MLD, rV5-V60, COPD and FEV1 were associated 
with severe RP (p<0.05). In multivariate analysis, NTCP (p=0.001) and 
rV10(p=0.015) was the most signiﬁcant factors associated with severe 
(grade≥3) radiation pneumonitis. The incidences of Grade≥3 pneumo-
nitis in the group with NTCP>4.2% and NTCP <4.2% were 43.5% and 
1.4%, respectively (p<0.01). The incidences of Grade≥3 pneumonitis in 
the group with rV10 <51.2% and rV10 >51.2% were 5.6% and 30.4%, 
respectively (p<0.01).
Conclusions: NTCP and rV10 is useful indicator of risk for develop-
ment of severe (grade≥3) radiation pneumonitis in NSCLC patients 
after concurrent chemotherapy and intensity -modulated radiotherapy 
(IMRT).
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A multicenter phase II randomized study of paclitaxel (P) and 
carboplatin (C) versus oral vinorelbine (oV) and carboplatin (C) as 
second-line treatment in patients with non-small cell lung cancer 
(NSCLC) pretreated with non-platinum based chemotherapy
Agelidou, A.1 Agelaki, S.2 Chandrinos, V.1 Polyzos, A.1 Agelidou, 
M.1 Papakotoulas, P.1 Kentepozidis, N.1 Giassas, S.1 Kalbakis, K.2 
Georgoulias, V.2 
1 Hellenic Oncology Research Group, Athens, Greece 2 Hellenic Oncol-
ogy Research Group, Heraklion, Greece 
Background: Limited data is available on the activity of platinum-
containing doublets as second-line treatment of NSCLC patients who 
received non-patinum based ﬁrst-line therapy. We performed a multi-
center randomized phase II trial to compare PC and oVC in NSCLC 
patients (pts) pretreated with ﬁrst-line docetaxel (D)/gemcitabine (G).
Methods: Pts with stage IIIB/IV NSCLC and adequate performance 
status (PS), haematological, hepatic, cardiac and renal function pre-
treated with DG were eligible. Pts received P 140 mg/m2 combined 
with C AUC3 or oV 45 mg/m2 combined with C AUC3 on days 1 and 
15 of a 30-day cycle. Stratiﬁcation was done for PS and response to 
prior treatment. Primary endpoint was response rate (RR) and second-
ary endpoints were time to progression (TTP), survival and toxicity. 
Results: 140 pts were randomized to PC (n= 65) or oVG (n= 75). 
Median age was 60 yrs for both arms (range, 39-74 and 38-79, respec-
tively) and PS was 0-1 in 91% and 85%, for PC and oVC, respectively. 
In an intension-to-treat analysis, signiﬁcantly more responders were ob-
served in the PC arm with an overall RR of 19.4% vs 4.2% (p=0.006). 
After a median follow up time of 5.4 (range 0.5-30) months, median 
TTP was 3.2 (range, 0.5-23.7) vs 2.8 (range, 0.5-18.5) for PC and 
oVC, respectively (p=0.150). Median overall survival was 6.3 (range, 
0.5–26.2) vs 6.1 (range, 0.5–30) months and 1-yr survival was 29.4% 
vs 27.5% for PC and oVC, respectively (p=0.586). The two arms ex-
hibited similar rates of grade 3 and 4 toxicity. 
Conclusions: A higher response rate that was not translated to a sur-
vival beneﬁt was recorded for the PC arm. No signiﬁcant differences in 
toxicity rates were observed. 
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A phase II trial of weekly cisplatin and docetaxel in advanced non-
small cell lung cancer (NSCLC)
Sovak, Mika A. Lutzker, Stuart Guensch, Lisa Joyce, Margaret 
Schwartz, Susan Wu, Yujun Zheng, Ling Aisner, Joseph 
The Cancer Institute of New Jersey, New Brunswick, NJ, USA
Background: Every 3-week cisplatin doublets used to treat advanced 
NSCLC carry a signiﬁcant risk of renal and other toxicities and can 
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